ABSTRACT
Background To support heterologous vaccine regimens, periodic SARS-CoV-2 revaccination required immunogenicity and safety data for adjuvanted protein-based vaccines following prior mRNA doses.
Methods This phase 3, open-label study (2019nCoV-312/NCT05875701) enrolled participants who received one dose of ancestral SARS-CoV-2 protein-based vaccine (NVX-CoV2373) in an earlier study (2019nCoV-307/NCT05463068) after a primary series and possibly one additional dose of mRNA vaccine. In the current study, participants received an additional dose of protein-based vaccine (ancestral [n=104] or Omicron BA.5 [n=40]) at least 180 days after their previous study dose. The primary objective was demonstration of noninferiority of neutralizing antibody (nAb) titers induced by the dose in this study versus the first dose of NVX-CoV-2373 in the earlier study. Safety was also evaluated.
Results A total of 144 participants were enrolled. The ratio of anti-Wuhan nAbs (GMT, IU/mL [95% CI]) at Day 28 after this study dose (ancestral 393.2 [318.0–468.2]) versus previous study dose (396.6 [328.7–478.6]) was 1.0 (0.8, 1.2), meeting noninferiority. The seroresponse rate difference between doses was 7.4% (95% CI = −1.2%–16.5%), also meeting noninferiority. Omicron BA.5 nAb titers suggest cross-protection against emerging variants. The nAb ratio at Day 28 between Omicron dose in this study (835.0 [597.1–1167.6]) versus previous study ancestral dose (436.0 [305.6–622.2]) was 1.9 (1.5–2.5), exceeding superiority criterion. Local and systemic reactions were similar between doses and strains in both studies.
Conclusions A heterologous regimen of two adjuvanted recombinant spike protein-based vaccine doses after mRNA vaccination produced robust immune responses, exhibiting cross-reactivity to newer variants.
Competing Interest Statement
Disclosure of potential conflicts of interest: JMA and PB are investigators in the 2019nCoV-312 study. JMA is also an investigator in COVID vaccine studies with GSK, Moderna, Inc, Pfizer Inc, Medicago Inc, and CyanVac LLC. RC, GC, RK, SCC, MZ, ZC, ME, JSP, RMM, and LMD are current employees or consultants at Novavax, Inc and may hold stock in the company.
Clinical Trial
NCT05875701
Funding Statement
This study was funded by Novavax, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of Advarra, Inc. gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This study was funded by Novavax, Inc.
Disclosure statement: This study was funded by Novavax, Inc.
CLINICAL IMPLICATIONS: Multiple doses of the adjuvanted rS protein-based vaccine can be administered safety in sequential heterologous series of vaccines and can produce robust immune responses regardless of prior COVID-19 vaccine history.
ABBREVIATIONS: AE (adverse event) · AESI (adverse event of special interest) · BMI (body mass index) · CI (confidence interval) · COVID-19 (coronavirus disease 2019) · ELISA (enzyme-linked immunosorbent assay) · FDA (Food and Drug Administration) · GMEU (geometric mean ELISA units) · GMFR (geometric mean fold rise) · GMR (geometric mean ratio) · GMT (geometric mean titer) · hACE2 (human angiotensin-converting enzyme 2) · IgG (immunoglobulin G) · LB (lower bound) · LLOQ (lower limit of quantitation) MAAE (medically attended adverse event) · mRNA (messenger ribonucleic acid) · nAb (neutralizing antibody) · NP (nucleoprotein) · PCR (polymerase chain reaction) · PP (per protocol) · rS (recombinant spike) · SAE (serious adverse event) · SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) · SCR (seroconversion rate) · TEAE (treatment emergent adverse event) · US (United States) · WHO (World Health Organization)
Disclosure of potential conflicts of interest: JMA and PB are investigators in the 2019nCoV-312 study. JMA is also an investigator in COVID vaccine studies with GSK, Moderna, Inc, Pfizer Inc, Medicago Inc, and CyanVac LLC. RC, GC, RK, SCC, MZ, ZC, ME, JSP, RMM, and LMD are current employees or consultants at Novavax, Inc and may hold stock in the company.
Data Availability
Study information is available online at links provided. Requests submitted to the corresponding author will be considered.
https://www.clinicaltrials.gov/study/NCT05875701?term=2019nCoV-312&rank=1
https://www.clinicaltrials.gov/study/NCT05463068?term=NCT05463068&rank=1
